PACT Inhibitors
The class of chemicals known as PACT Inhibitors encompasses a diverse range of compounds capable of directly or indirectly modulating PACT, a protein involved in cellular processes such as antiviral defense and RNA processing. Among these inhibitors, Cisplatin stands out as an indirect inhibitor that induces DNA damage, triggering cell cycle arrest and apoptosis, thus impacting cellular processes associated with PACT. Staurosporine, a broad-spectrum kinase inhibitor, indirectly modulates PACT by affecting multiple signaling pathways involved in its expression or activity. Thapsigargin, through the disruption of calcium homeostasis, indirectly influences PACT by perturbing downstream signaling cascades related to calcium-mediated pathways. Geldanamycin inhibits heat shock protein 90 (HSP90), impacting the stability of client proteins, and thereby modulating cellular processes linked to PACT. Trichostatin A, a histone deacetylase (HDAC) inhibitor, indirectly regulates PACT by influencing epigenetic pathways involved in its expression or activity.
Camptothecin, a topoisomerase I inhibitor, induces DNA damage, leading to cell cycle arrest and apoptosis, affecting cellular processes associated with PACT. PD98059, a selective MEK inhibitor, indirectly modulates PACT by affecting the MAPK/ERK pathway. Rapamycin inhibits the mTOR pathway, impacting cellular processes linked to PACT. SB203580, a selective p38 MAPK inhibitor, indirectly regulates PACT by affecting the p38 MAPK pathway. Actinomycin D inhibits transcription by intercalating with DNA, influencing RNA synthesis and, consequently, cellular processes associated with PACT. 17-AAG, an HSP90 inhibitor, indirectly modulates PACT by affecting the stability of client proteins. In summary, the PACT Inhibitors class provides insight into the intricate mechanisms through which a variety of chemicals can influence PACT, highlighting the complexity of cellular responses associated with the modulation of this multifunctional protein.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin is a platinum-containing chemotherapeutic that forms DNA adducts, inducing DNA damage. This can trigger cell cycle arrest and apoptosis, impacting cellular processes associated with PACT. Cisplatin acts as an indirect inhibitor by influencing DNA integrity and pathways linked to PACT. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that can impact multiple signaling pathways. Its ability to inhibit kinases involved in cellular processes associated with PACT makes it an indirect inhibitor by modulating pathways influencing the expression or activity of PACT. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) pump. Perturbation of calcium levels can modulate cellular processes linked to PACT, making Thapsigargin an indirect inhibitor by influencing downstream signaling cascades related to calcium-mediated pathways. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C is an antitumor antibiotic that forms DNA crosslinks, leading to DNA damage. Its impact on DNA integrity can trigger cell cycle arrest and apoptosis, influencing cellular processes associated with PACT. Mitomycin C acts as an indirect inhibitor by modulating DNA-related pathways linked to PACT. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin inhibits heat shock protein 90 (HSP90), affecting the stability of client proteins. Since HSP90 is involved in cellular processes associated with PACT, Geldanamycin can act as an indirect inhibitor by modulating pathways that influence the expression or activity of PACT. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor that can impact gene expression. Its ability to modulate the acetylation status of histones and other proteins involved in cellular processes associated with PACT makes it an indirect inhibitor by influencing pathways linked to epigenetic regulation. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin is a topoisomerase I inhibitor that induces DNA damage. Its impact on DNA integrity can trigger cell cycle arrest and apoptosis, influencing cellular processes associated with PACT. Camptothecin acts as an indirect inhibitor by modulating DNA-related pathways linked to PACT. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective MEK inhibitor affecting the MAPK/ERK pathway. Its inhibition of MEK can modulate downstream signaling cascades involved in cellular processes associated with PACT, making PD98059 an indirect inhibitor by influencing pathways that impact the expression or activity of PACT. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway, impacting cellular processes associated with PACT. Its inhibition of mTOR can modulate downstream signaling cascades involved in cellular processes linked to PACT, making Rapamycin an indirect inhibitor by influencing pathways that impact the expression or activity of PACT. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective p38 MAPK inhibitor affecting the p38 MAPK pathway. Its inhibition of p38 MAPK can modulate downstream signaling cascades involved in cellular processes associated with PACT, making SB203580 an indirect inhibitor by influencing pathways that impact the expression or activity of PACT. | ||||||